Consequently, overexpression of wild type NSUN2, but not the catalytic mutant NSUN2, leads to gefitinib resistance and tumor recurrence, while depletion of NSUN2 results in tumor regression and overcomes intrinsic resistance to gefitinib. This evidence concerns the gene NSUN2 and neoplasm.